Neutrophil Elastase as a target in lung cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 6, 2012, Pages 565-579

  Moroy, Gautier ^a   Alix, Alain J P ^b   Sapi, Janos ^b   Hornebeck, William ^b   Bourguet, Erika ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

(Dual) inhibitors; Bifunctionality; Lung cancer; Neutrophil Elastase

Indexed keywords

ALPHA 1 ANTITRYPSIN; BENZOXAZINONE DERIVATIVE; CAFFEIC ACID; CAFFEIC ACID PHENETHYL ESTER; CEPHALOSPORIN; CHONDROITIN 6 SULFATE; COUMARIN; DERMATAN SULFATE; ELAFIN; ELAIDIC ACID; ELASTIN; EPIGALLOCATECHIN GALLATE; GELATINASE A; GLYCOSAMINOGLYCAN; HEPARIN; ISOCOUMARIN DERIVATIVE; LEUKOCYTE ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; N HYDROXYSUCCINIMIDE; OLEIC ACID; PALMITIC ACID; PALMITOLEIC ACID; PARINARIC ACID; PEPTIDE DERIVATIVE; PYRONE DERIVATIVE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; STEARIC ACID; UNINDEXED DRUG; UNSATURATED FATTY ACID;

ANTICOAGULATION; BINDING SITE; CANCER RISK; CHEMICAL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DNA DAMAGE; ENZYME INHIBITION; ENZYME SPECIFICITY; FREEZE DRYING; HUMAN; HYDROLYSIS; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG CANCER; MOLECULAR DOCKING; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84861684968     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800617696     Document Type: Review

References (129)

1. Brody, J.S.; Spira, A. Chronic obstructive pulmonary disease, inflammation and lung cancer. Proc. Am. Thorac. Soc., 2006, 3, 535-538.
2. Houghton, A.M.; Mouded, M.; Shapiro, S.D. Commons origins of lung cancer and COPD. Nature Medicine, 2008, 14(10), 1023-1024.
3. Komarova, E.A.; Krivokrysenko, V.; Wang, K.; Neznanov, N.; Chernov, M.V.; Komarov, P.G., Brennan, M.L.; Golovkina, T.V.; Rokhlin, O.W.; Kuprash, D.V.; Nedospasov, S.A.; Hazen, S.L.; Feinstein, E.; Gudkov, A.V. p53 is a suppressor of inflammatory response in mice. FASEB J., 2005, 19(8), 1030-1032.
4. Mannino, D.M.; Aguayo, S.M.; Petty, T.L.; Redd, S.C. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey followup. Arch. Intern. Med., 2003, 163(12), 1475-1480.
5. de Torres, J.P.; Bastarrika, G.; Wisnivesky, J.P.; Alcaide, A.B.; Campo, A.; Seijo, L.M.; Pueyo, J.C.; Villanueva, A.; Lozano, M.D.; Montes, U.; Montuenga, L.; Zulueta, J.J. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest, 2007, 132(6), 1932-1938.
6. Lopez-Encuentra, A.; Astudillo, J.; Cerezal, J.; Gonzalez-Aragoneses, F.; Novoa, N.; Sanchez-Palencia, A. Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur. J. Cardiothorac. Surg., 2005, 27(1), 8-13.
7. Wood, A.M.; Stockley, R.A. Alpha-1-antitrypsin deficiency: From gene to treatment. Respiration, 2007, 74, 481-492.
8. Mulgrew A.T.; Taggart, C.C.; McElvaney, N.G. Alpha-1-antitrypsin deficiency: current concepts. Lung, 2007, 185(4), 191-201.
9. Sun, Z.; Yang, P. Role of imbalance between neutrophil elastase and a1-antitrypsin in cancer development and progression. The Lancet Oncology, 2005, 5, 182-190.
10. Topic, A.; Ljujic, M.; Nikolic, A.; Petrovic-Stanojevic, N.; Dopudja-Pantic, V.; Mitic-Milikic, M.; Radojkovic, D. Alpha-1-antitrypsin phenotypes and neutrophil elastase gene promoter polymorphisms in lung cancer. Pathol. Oncol. Res., 2011, 17(1), 75-80.
11. Yang, P.; Bamlet, W.R.; Sun, Z.; Ebbert, J.O.; Aubry, M.C.; Krowka, M.J.; Taylor, W.R.; Marks, R. S; Deschamps, C.; Swensen, S.J.; Wieben, E.D.; Cunningham, J.M.; Melton, L.J.; de Andrade, M. Alpha-1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest, 2005, 128(1), 445-452.
12. Korkmaz, B.; Moreau, T.; Gauthier, F. Neutrophil elastase, proteinase 3 and cathepsin G: Physicochemical properties, activity and physiopathological functions. Biochimie, 2008, 90, 227-242.
13. Snider, G.L.; Ciccolella, D.E.; Morris, S.M.; Stone, P.J.; Lucey, E.C. Putative role of Neutrophil Elastase in the pathogenesis of emphysema. Ann. N.Y. Acad. Sci., 1991, 624, 45-59.
14. Zhang, Z.; Winyard, P.G.; Chidwick, K.; Murphy, G.; Wardell, M.; Carrell, R.W.; Blake, D.R. Proteolysis of human native and oxidized alpha 1-proteinase inhibitor by matrilysin and stromelysin. Biochim. Biophys. Acta, 1994, 1199(2), 224-228.
15. Owen, C. Leukocyte cell surface proteinases: Regulation of expression, functions, and mechanisms of surface localization. Int. J. Biochem. Cell Biol., 2008, 40, 1246-1272.
16. Hornebeck, W.; Emonard, H. The cell-elastin-elastase(s) interacting triade directs elastolysis. Front. Biosci., 2011, 16, 707-722.
17. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420(6917), 860-867.
18. Demaria, S.; Pikarsky, E.; Karin, M.; Coussens, L.M.; Chen, Y.C.; El-Omar, E.M.; Trinchieri, G.; Dubinett, S.M.; Mao, J.T.; Szabo, J.T.; Krieg, A.; Weiner, G.J.; Fox, B.A.; Coukos, G.; Wang, E.; Abraham, R.T.; Carbone, M.; Lotze, M.T. Cancer and inflammation: promise for biologic therapy. J. Immunother., 2010, 33(4), 335-351.
19. Bellocq, A.; Antoine, M.; Flahault, A.; Philippe, C.; Crestani, B.; Bernaudin, J.-F.: Mayaud, C.; Milleron, B.; Baud, L.; Cadrane, J. Neutrophil alveolis in bronchioalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am. J. Pathol., 1998, 152(1), 83-92.
20. Yamashita, J.; Ogawa, M.; Shirakusa, T. Free-form neutrophil elastase is an independent marker predicting recurrence in primary breast cancer. J. Leukoc. Biol., 1995, 57(3), 375-378.
21. Sato, T.; Takahashi, S.; Mizumoto, T.; Harao, M.; Akizuki, A.; Takasugi, M.; Fukutomi, T.; Yamashita, J-I. Neutrophil elastase and cancer. Surg. Onc., 2006, 15, 217-222.
22. Yamashita, J-I.; Ogawa, M.; Abe, M.; Hayashi, N.; Kurusu, Y.; Kawahara, K.; Shirakusa, T. Tumor neutrophil elastase is closely associated with the direct extension of non-small cell lung cancer into the aorta. Chest, 1997, 111, 885-890.
23. Park, J.Y.; Chen, L.; Lee, J.; Sellers, T.; Tockman, M.S. Polymorphisms in the promoter region of neutrophil elastase gene and lung cancer risk. Lung Cancer, 2005, 48(3), 315-321.
24. Fukushima, M.; Fukuda, Y.; Kawamoto, M.; Yamanaka, N. Elastosis in lung carcinoma: immunohistochemical, ultrastructural and clinical studies. Pathol. Int., 2000, 50(8), 625-635.
25. Eto, T.; Suzuki, H.; Honda, A.; Nagashima Y. The changes of the stromal elastolitic framework in the growth of peripheral lung adenocarcinomas. Cancer, 1996, 77(4), 646-656.
26. Antonicelli, F.; Bellon, G.; Debelle, L.; Hornebeck, W. Elastinelastases and inflamm-aging. Curr. Top. Dev. Biol., 2007, 79, 99-155.
27. Alix, A.J.P. A critical turn in the knowledge of the structure/function/activity of elastin. J. Soc. Biol. (Fr), 2001, 195, 181-193.
28. Duca, L.; Floquet, N.; Alix, A.J.P.; Haye, B.; Debelle, L. Elastin as a matrikin. Crit. Rev. oncol/hemat., 2004, 49, 235-244.
29. Timar, J.; Lapis, K.; Fulop, T.; Varga, Z.S.; Tixier, J.M.; Robert, L.; Hornebeck, W. Interaction between elastin and tumor cell lines with different metastatic potential; in vitro and in vivo studies. J. Cancer Res. Clin. Oncol., 1991, 117(3), 232-238.
30. Hornebeck, W.; Maquart, F.-X. Proteolyzed matrix as a template for the regulation of tumor progression. Biomed., Pharmacother., 2003, 57(5-6), 223-230.
31. Hornebeck, W.; Robinet, A.; Duca, L.; Antonicelli, F.; Wallach, J.; Bellon, G. The elastin-connexion and melanoma progression. Anticancer Res., 2005, 25(4), 2617-2625.
32. Moroy, G.; Alix, A.J.P.; Héry-Huynh, S. Structural characterization of human elastin derived peptides containing GXXP sequence. Biopolymers, 2005, 78(4), 206-220.
33. Hougton, A.M.; Rzymkiewicz, D.M.; Ji, H.; Gregory, A.D.; Egea, E.E.; Metz, H.E.; Stolz, D.B.; Land, S.R.; Marconcini, L.A.; Kliment, C.R.; Jenkins, K.M., Beaulieu, K.A.; Mouded, M.; Frank, S.J.; Wong, K.K.; Shapiro, S.D. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nature Medicine, 2010, 16(2), 219-224.
34. Houghton, A.M. The paradox of tumor-associated neutrophils: Fueling tumor growth with cytotoxic substances. Cell Cycle, 2010, 9(9), 1732-1737.
35. Fingleton, B. Inflammatory proteinase slips into tumor cells. Nature Medicine, 2010, 16(2), 161-163.
36. Nguyen, H.H.; Aronchik, I.; Brar, G.A.; Bjeldanes, L.F.; Firestone, G.L. The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing. Proc. Natl. Acad. Sci. USA, 2008, 105(50), 19750-19755.
37. Aronchik, I.; Bjeldanes, L.F.; Firestone, G.L. Direct inhibition of elastase activity by indole-3-carbinol triggers a CD40-TRAF regulatory cascade that disrupts NF-KB transcriptional activity in human breast cancer cells. Cancer Res., 2010, 70(12), 4961-4971.
38. Vandivier, R.W.; Fadok, V.A.; Hoffmann, P.R.; Bratton, D.L.; Penvari, C.; Brown, K.K.; Brain, J.D.; Accurso, F.J.; Henson, P.M. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystis fibrosis and bronchiectasis. J. Clin. Invest., 2002, 109(5), 661-670.
39. Moreau, T.; Baranger, K.; Dadé, S.; Dalet-Choisy S.; Guyot, N.; Zani M.L. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie, 2008, 90, 284-295.
40. Im, H.; Woo, M.S.; Hwang, K.Y.; Yu, M.H. Interactions causing the kinetic trap in serpin protein folding. J. Biol. Chem., 2002, 277(48), 46347-46354.
41. Cooley, J.; Takayama, T.K.; Shapiro, S.D.; Schechter, N.M.; Remold-O'Donnell, E. The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochem., 2001, 40(51), 15762-15770.
42. Silverman, G.A.; Bird, P.I.; Carrell, R.W.; Church, F.C.; Coughlin, P.B.; Gettins, P.G.; Irving, J.A.; Lomas, D.A.; Luke, C.J.; Moyer, R.W.; Pemberton, P.A.; Remold-O'Donnell, E.; Salvesen, G.S.; Travis, J.; Whisstock, J.C. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions and a revised nomenclature. J. Biol. Chem., 2001, 276(36), 3293-3296.
43. Tremblay, G.; Janelle, M.; Bourbonnais, Y. Anti-inflammatory activity of neutrophil elastase inhibitors. Curr. Opin. Investig. Drugs, 2003, 4(5), 556-565.
44. Thompson, R.C.; Ohlsson, K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc. Natl. Acad. Sci. USA, 1986, 83(16), 6692-6696.
45. Wiedow, O.; Schröder, J.-M.; Gregory, H.; Young, J.A.; Christophers, E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem., 1990, 265, 14791-14795.
46. Francart, C.; Dauchez, M.; Alix, A.J.P.; Lippens, G. Solution structure of R-elafin, a specific inhibitor of elastase. J. Mol. Biol., 1997, 268, 666-677.
47. Bode, W.; Meyer, E. Jr; Powers, J.C. Human leukocyte and porcine pancreatic elastase: Xray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors. Biochemistry, 1989, 28(5), 1951-1963.
48. Koizumi, M.; Fujino, A.; Fukushima, K.; Kamimura, T.; Takimoto-Kamimura, M. Complex of human neutrophil elastase with. SLPI. J. Synchrotron Radiat., 2008, 15(3), 308-311.
49. Tsunemi, M.; Matsuura, Y.; Sakakibara, S.; Katsube, Y. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 Å resolution. Biochemistry, 1996, 35(36), 11570-11576.
50. Guyot, N.; Zani, M-L.; Maurel, M-C.; Dallet-Choisy, S.; Moreau, T. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry, 2005, 44, 15610-15618.
51. Sallenave, J.M.; Shulmann, J.; Crossley, J.; Jordana, M.; Gauldie, J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/Elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. J. Respir. Cell Mol. Biol., 1994, 11(6), 733-741.
52. Zani, M-L.; Baranger, K.; Guyot, N.; Dallet-Choisy, S.; Moreau, T. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases. Protein Science, 2009, 18, 579-584.
53. Delcourt, C.; Hérigault, S.; Delclaux, C.; Poncin, A.; Levane, M.; Harf, A.; Saudubray, F.; Lafuma, C. Protection against acute lung injury by intravenous or intracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am. J. Respir. Cell Mol. Biol., 2002, 26, 290-297.
54. Rees, D.D.; Rogers, R.A.; Cooley, J.; Mandle, R.J.; Kenney, D.M.; Remold-O'Donnell, E. Recombinant human monocyte/neutrophil elastase inhibitor protects rat lungs against injury from cystic fibrosis airway secretions. Am. J. Respir. Cell Mol. Biol., 1999, 20(1), 69-78.
55. Doucet, A.; Bouchard, D.; Janelle, M.F.; Bellemare, A.; Gagné, S.; Tremblay, G.M.; Bourbonnais, Y. Characterization of human preelafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema. Biochem. J., 2007, 405(3), 455-463.
56. Redini, F.; Tixier, J.-M.; Petitou, M.; Choay, J.; Robert, L.; Hornebeck, W. Inhibition of leucocyte elastase by heparin and its derivatives. Biochem. J., 1988, 252, 515-519.
57. Lafuma, C.; Frisdal, E.; Harf, A.; Robert, L.; Hornebeck, W. Prevention of leucocyte elastase-induced emphysema in mice by heparin fragments. Eur. Respir. J., 1991, 4(8), 1004-1009.
58. Spencer, J.L.; Stone, P.J.; Nugent, M.A. New insights into the inhibition of human neutrophil elastase by heparin. Biochemistry, 2006, 45, 9104-9120.
59. Schenker, P.; Baici, A. Paradoxical interactions between modifiers and elastase-2. FEBS J., 2010, 277, 2486-2495.
60. Casu, B.; Vlodavsky, I.; Sanderson, R.D. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol. Haemost. Throm., 2007, 8(36), 195-203.
61. Fryer, A.; Huang, Y.C.; Rao, G.; Jacoby, D.; Mancilla, E.; Whorton, R.; Piantadosi, C.A.; Kennedy, T.; Hoidal, J. Selective Odesulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J. Pharmacol. Exper. Therapeut., 1997, 282(1), 208-219.
62. Lee, D.Y.; Park, K.; Kim, S.K.; Park, R.W.; Kwon, I.C.; Kim, S.Y.; Byun, Y. Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis. Clin. Cancer Res., 2008, 14(9), 2841-2849.
63. Yu, L.; Garg, H.G.; Li, B.; Linhardt, R.J.; Hales, C.A. Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats. Curr. Cancer Drug Targets, 2010, 10(2), 229-241.
64. Baici, A.; Diczhazi, C.; Neszmélyi, A.; Moczar, E.; Hornebeck, W. Inhibition of the human leukocyte endopeptidase elastase and cathepsin G and of porcine pancreatic elastase by N-oleoyl derivatives of heparin. Biochem. Pharmacol., 1993, 46(9), 1545-1549.
65. Siedle, B.; Hrenn, A.; Merfort, I. Natural compounds as inhibitors of human neutrophil elastase. Planta Med., 2007, 73(5), 401-420.
66. Johnson, I.T. Green tea and cancer. Lancet Oncol., 2010, 11(6), 519-520.
67. Cao, Y.; Cao, R. Angiogenesis inhibited by drinking tea. Nature, 1999, 398(6726), 381.
68. Hazgui, S.; Bonnomet, A.; Nawrocki-Raby, B.; Milliot, M.; Terryn, C.; Cutrona, J.; Polette, M.; Birembaut, P.; Zahm, J.M. Epigallocatechin-3-gallate (EGCG) inhibits the migratory behavior of tumor bronchial epithelial cells. Respir. Res., 2008, 9(1), 33.
69. Melzig, M.F.; Löser, B.; Lobitz, G.O.; Tamayo-Castillo, G.; Merfort, I. Inhibition of granulocyte elastase activity by caffeic acid derivatives. Pharmazie, 1999, 54(9), 712.
70. Melzig, M.F.; Löser, B.; Ciesielski, S. Inhibition of neutrophil elastase activity by phenolic compounds from plants. Pharmazie, 2001, 56(12), 967-970.
71. Chen, M.F.; Keng, P.C.; Lin, P.Y.; Yang, C.T.; Liao, S.K.; Chen, W.C. Caffeic acid phenethyl ester decreases acute pneumonitis after irradiation in vitro and in vivo. BMC Cancer, 2005, 9(5), 158.
72. Gupta, S.C.; Kim, J.H.; Prasad, S.; Aggarwal, B.B. Regulation of survival, proliferation, invasion, angiogenesis and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev., 2010, 29, 405-434.
73. Chung, T.W.; Moon, S.K.; Chang, Y.C.; Ko, J.H.; Lee, Y.C.; Cho, G.; Kim, S.H.; Kim, J.G.; Kim, C.H. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism. FASEB J., 2004, 18(14), 1670-1681.
74. Sartor, L.; Pezzato, E.; Garbisa, S. (-)Epigallocatechin-3-gallate inhibits leukocyte elastase: potential of the phyto-factor in hindering inflammation, emphysema, and invasion. J. Leukoc. Biol., 2002, 71(1), 73-79.
75. Dell'Aica, I.; Caniato, R.; Biggin, S.; Garbisa, S. Matrix proteases, green tea, and St. John's wort: biomedical research catches up with folk medicine. Clin. Chim. Acta, 2007, 381(1), 69-77.
76. Hrenn, A.; Steinbrecher, T.; Labahn, A.; Schwager, J.; Schempp, C.M.; Merfort, I. Plant phenolics inhibit neutrophil elastase. Planta Med., 2006, 72(12), 1127-1131.
77. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-1662.
78. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46(1-3), 3-26.
79. Ashe, B.M.; Zimmerman, M. Specific inhibition of human granulocyte elastase by cis-unsaturated fatty acids and activation by the corresponding alcohols. Biochem. Biophys. Res. Commun., 1977, 75(1), 194-199.
80. Tyagi, S.C.; Simon, S.R. Inhibitors directed to binding domains in neutrophil elastase. Biochemistry, 1990, 29, 9970-9977.
81. Lafuma, C.; Fisdal, E.; Robert, L.; Moczar, E.; Lefrancier, P.; Hornebeck. W. Lipopeptides as bifunctional inhibitors: prevention of elastase-induced emphysema in mice by intratracheal pretreatment with Oleyl-Alanyl-Alanyl-Prolyl-Valine. Second forum on peptides. Eds Aubry, A.; Marraud, M.; Vitoux, B. Colloque INSERM/John Libbey Eurotext Ltd., 1989, 74, 321-324.
82. Kerneur, C.; Hornebeck, W.; Robert, L.; Moczar, E. Inhibition of human leukocyte elastase by fatty acyl-benzisothiasolinone, 1,1-dioxide conjugates (fatty acyl-saccharins). Biochem. Pharmacol., 1993, 45(9), 1889-1895.
83. Hornebeck, W.; Moczar, E.; Szecsi, J.; Robert, L. Fatty acid peptide derivatives as model compounds to protect elastin against degradation by elastases. Biochem. Pharmacol., 1985, 34(18), 3315-3321.
84. Berton, A.; Rigot, V.; Huet, E.; Decarme, M.; Eeckhout, Y.; Patthy, L.; Godeau, G.; Hornebeck, W.; Bellon, G.; Emonard, H. Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases A and B by long-chain unsaturated fatty acids. J. Biol. Chem., 2001, 276(23), 20458-20465.
85. Polette, M.; Huet, E.; Birembaut, P.; Maquart, F.-X.; Hornebeck, W.; Emonard, H. Influence of oleic acid on the expression, activation and activity of gelatinase A produced by oncogenetransformed human bronchial epithelial cells. Int. J. Cancer, 1999, 80(5), 751-755.
86. Moroy, G.; Bourguet, E.; Decarme, M.; Sapi, J.; Alix, A.J.P.; Hornebeck, W.; Lorimier, S. Inhibition of human leukocyte elastase, plasmin and matrix metalloproteinases by oleic acid and oleoyl-Galardin derivative(s). Biochem. Pharmacol., 2011, 81(5), 626-635.
87. Yamaki, T.; Yano, T.; Satoh, H.; Endo, T.; Matsuyama, C.; Kumagai, H.; Miyahara, M.; Sakurai, H.; Pokorny, J.; Shin, S.J.; Hagiwara, K. High oleic acid oil suppresses lung tumorigenesis in mice through the modulation of extracellular signal-regulated kinase cascade. Lipids, 2002, 37(8), 783-788.
88. Kimura, Y. Carp oil or oleic acid, but not linoleic acid or linolenic acid, inhibits tumor growth and metastasis in Lewis lung carcinoma-bearing mice. J. Nutr., 2002, 132(7), 2069-2075.
89. Satiroudis, T.G.; Kryptopoulos, S.A. Anticarcinogenic compounds of olive oil and related biomarkers. Eur. J. Nutr., 2008, 47(suppl. 2), 69-72.
90. Moroy, G.; Denhez, C.; El Mourabit, H.; Toribio, A.; Dassonville, A.; Decarme, M.; Renault, J.H.; Mirand, C.; Bellon, G.; Sapi, J.; Alix, A.J.P.; Hornebeck, W.; Bourguet, E. Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies. Bioorg. Med. Chem., 2007, 15(14), 4753-4766.
91. LeDour, G.; Moroy, G.; Rouffet, M.; Bourguet, E.; Guillaume, D.; Decarme, M.; ElMourabit, H.; Augé, F.; Alix, A.J.P.; Laronze, J.-Y.; Bellon, G.; Hornebeck, W.; Sapi, J. Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. Bioorg. Med. Chem., 2008, 16(18), 8745-8759.
92. Ferry, G.; Longchamp, M.; Pennel, L.; de Nanteuil, G.; Canet, E.; Tucker, G.C. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett., 1997, 402(2-3), 111-115.
93. Safranek, J.; Pesta, M.; Holubec, L.; Kulda, V.; Dreslerova, J.; Vrzalova, J.; Topolcan, O.; Pesek, M.; Finek, J.; Treska, V. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res., 2009, 29(7), 2513-2517.
94. Thomas, P.; Khokha, R.; Shepherd, F.A.; Feld, R.; Tsa, M.S. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol., 2000, 190(2), 150-156.
95. Qian, Q.; Wang, Q.; Zhan, P.; Peng, L.; Wei, S.Z.; Shi, Y.; Song Y. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with metaanalysis. Cancer Invest., 2010, 28(6), 661-669.
96. Spencer, R.W.; Copp, L.J.; Bonaventura, B.; Tam, T.F.; Liak, R.J.; Billedeau, R.J.; Krantz, A. Inhibition of serine proteases by benzoxazinones: effects of electron withdrawal and 5-substitution. Biochem. Biophys. Res. Commun., 1986, 140(3), 928-933.
97. Pochet, L.; Doucet, C.; Dive, G.; Wouters, J.; Masereel, B.; Reboud-Ravaux, M.; Pirotte, B. Coumarinic derivatives as mechanism-based inhibitors of m-chymotrypsin and human leukocyte elastase. Bioorg. Med. Chem., 2000, 8(6), 1489-1501.
98. Harper, J.W.; Hemmi, K.; Powers, J.C. Reaction of serine proteases with substituted isocoumarins: discovery of 3,4-dichloroisocoumarin, a new general mechanism based serine protease inhibitor. Biochemistry, 1985, 24(8), 1831-1841.
99. Gelb, M.H.; Abeles, R.H. Mechanism of inactivation of chymotrypsin by 3-benzyl-6-chloro-2-pyrone. Biochemistry, 1984, 23(26), 6596-6604.
100. 31P Nuclear Magnetic Resonance spectroscopy. Biochemistry, 1991, 30(17), 4132-4136.
101. Shah, S.K.; Dorn, C.P.; Finke, P.E.; Hale, J.J.; Hagmann, W.K.; Brause, K.A.; Chandler, O.G.; Kissinger, A.L.; Ashe, B.M.; Weston, H.; Knight, W.B.; Maycock, A.L.; Dellea, P.S.; Fletcher, D.S.; Hand, K.M.; Mumford, R.A.; Underwood, D.J.; Doherty, J.B. Orally active O-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones. J. Med. Chem., 1992, 35(21), 3745-3754.
102. Knight, W.B.; Maycock, A.L.; Green, B.G.; Ashe, B.M.; Gale, P.; Weston, H.; Finke, P.E.; Hagmann, W.K.; Shah, S.K.; Doherty, J.B. Mechanism of inhibition of human leukocyte elastase by two cephalosporin derivatives. Biochemistry, 1992, 31(21), 4980-4986.
103. Shah, S.K.; Brause, K.A.; Chandler, G.O.; Finke, P.E.; Ashe, B.M.; Weston, H.; Knight, W.B.; Maycock, A.L.; Doherty, J.B. Inhibition of human leukocyte elastase. 3. Synthesis and activity of 3'-substituted cephalosporins. J. Med. Chem., 1990, 33(9), 2529-2535.
104. 1-oxazolidin-2,4-dion-5-ylsubstituted-lactams as novel inhibitors of human leukocyte elastase. J. Med. Chem., 2005, 48(15), 4861-4870.
105. Knight, W.B.; Swiderek, K.M.; Sakuma, T.; Calaycay, J.; Shively, J.E.; Lee, T.D.; Covey, T.R.; Shushan, B.; Green, B.G.; Chabin, R.; Shah, S.; Mumford, R.; Dickinson, T.A.; Griffin, P.R. Electrospray ionization mass spectrometry as a mechanistic tool: mass of human leucocyte elastase and a l-lactam-derived E-I complex. Biochemistry, 1993, 32(8), 2031-2035.
106. Wakselman, M.; Joyeau, R.; Kobaiter, R.; Boggetto, N.; Vergely, I.; Maillard, J.; Okochi, V.; Montagne, J.J.; Reboud-Ravaux, M. Functionalized N-aryl azetidinones as novel mechanism-based inhibitors of neutrophil elastase. FEBS Lett. 1991, 282(2), 377-381.
107. Mulchande, J.; Guedes, R.C.; Tsang, W.-Y.; Page, M.I.; Moreira, R.; Iley, J. Azetidine-2,4-diones (4-oxo-R-lactams) as scaffolds for designing elastase inhibitors. J. Med. Chem., 2008, 51(6), 1783-1790.
108. Zimmerman, M.; Morman, H.; Mulvey, D.; Jones, H.; Frankshun, R.; Ashe B.M. Inhibition of elastase and other serine proteases by heterocyclic acylating agents. J. Biol. Chem., 1980, 255(20), 9848-9851.
109. Groutas, W.C.; Kuang, R.; Venkataraman, R.; Epp, J.B.; Ruan, S.; Prakash, O. Structure-based design of a general class of mechanism-based inhibitors of the serine proteinases employing a novel amino acid-derived heterocyclic scaffold. Biochemistry, 1997, 36(16), 4739-4750.
110. He, G.; Dou, D.; Wei, L.; Alliston, K.R.; Groutas, W.C. Inhibitors of human neutrophil elastase based on a highly functionalized Namino-4-imidazolidinone scaffold. Eur. J. Med. Chem., 2010, 45(9), 4280-4287.
111. Abraham, C.J.; Pauli, D.H.; Dogo-Isonagie, C.; Lectka, T. Diastereoselective synthesis of trans-β-lactams using a simple multifunctional catalyst. Synlett., 2009, 1651-1654.
112. Zhang Y.-R.; He, L.; Wu, W.; Shao, P.-L.; Ye, S. Chiral Nheterocyclic carbene catalyzed Staudinger reaction of ketenes with imines: Highly enantioselective synthesis of N-Boc β-lactams. Org. Lett., 2008, 10, 277-280.
113. Lee, E.C.; Hodous, B.L.; Bergin, E.; Shih, C.; Fu, G.C. Catalytic asymmetric Staudinger reactions to form β-lactams: An unanticipated dependence of diastereoselectivity on the choice of the nitrogen substituent. J. Am. Chem. Soc., 2005, 127, 11586-11587.
114. Yi, H.; Cho, H.J.; Cho, S.M.; Lee, D.G.; Abd El-Aty, A.; Yon, S.J.; Bae, G.W.; Nho, K.; Kim, B.; Lee, C.H.; Kim, J.S.; Barlett, M.G.; Shin, H.C. Pharmacokinetic properties and antitumor efficacy of the fluorouracil loaded PEG-hydrogel. BMC Cancer, 2010, 18(10), 211.
115. Cantin, A.M.; Wods, D.E.; Cloutier, D.; Dufour, E.K.; Leduc, R. Polyethylene glycol conjugation at Cys232 prolongs the half-time of alpha1 proteinase inhibitor. Am. J. Respir. Cell Mol. Biol., 2002, 27(6), 659-665.
116. Guarnieri, F.; Spencer, J.L.; Lucey, E.C., Nugent, M.A.; Stone, P.J. A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema. Proc. Natl Acad. Sci. USA, 2010, 107(23), 10661-10666.
117. Ghaedi, M.; Lotfi, A.S.; Soleimani, M. Establishment of lentiviralvector-mediated model of human alpha-1 antitrypsin delivery into hepatocyte-like cells differentiated from mesenchymal stem cells. Tissue Cell, 2010, 42(3), 181-189.
118. Moroy, G.; Ostuni, A.; Pepe, A.; Tamburro, A.M.; Alix, A.J.P.; Héry-Huynh S. A proposed interaction mechanism between elastinderived peptides and the elastin/laminin receptor-binding domain. Proteins, 2009, 76(2), 461-476.
119. Brassard, B.; Fuchs, P.; Huet, E.; Alix, A.J.P.; Wallach, J.; Tamburro, A.M.; Delacoux, F.; Haye, B.; Emonard H.; Hornebeck, W.; Debelle, L. Conformational dependance of MMP1 upregulation by elastin peptides in cultured fibroblasts. J. Biol. Chem., 2001, 276, 5222-5227.
120. Floquet, N.; Héry-Huynh, S.; Dauchez, M.; Derreumaux, P.; Tamburro, A.M.; Alix, A.J.P. Structural characterization of VGVAPG, an elastin-derived-peptide. Biopolymers, 2004, 76(3), 266-280.
121. Huey, R.; Morris, G.M.; Olson, A.J.; Goodsell, D.S. A semi empirical free energy force field with charge-based desolvation. J. Comput. Chem., 2007, 28(6), 1145-1152.
122. Software free of charge, developed (2009) by Sayle, R. at Biomolecular Structures Group, Glaxo Wellcome Research & Development.
123. Bernstein, H.J. 2009, http://www.bernstein-plussons.com/software/rasmol/.
124. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res., 2000, 28(1), 235-242.
125. DeLano, W.L. The PyMol Molecular Graphics System, Palo Alto, CA. USA. 2002, http://www.pymol.org.
126. Wang, Y.; Xiao, J.; Suzek, T.O.; Zhang, J.; Wang, J.; Bryant, S.H. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res., 2009, 37(Web Server issue), W623-633.
127. Bode, W.; Wei, A.Z.; Huber, R.; Meyer, E.; Travis, J.; Neumann, S. X-ray crystal structure of the complex of human leukocyte elastase (PMN Elastase) and the third domain of the turkey ovomucoid inhibitor. EMBO J., 1986, 5(10), 2453-2458.
128. Li, H.; Robertson, A.D.; Jensen, J.H. Very fast empirical prediction and rationalization of protein pKa values. Proteins, 2005, 61(4), 704-721.
129. Bas, D.C.; Rogers, D. M; Jensen, J.H. Very fast prediction and rationalization of pKa values for protein-ligand complexes. Proteins, 2008, 73(3), 765-783.